Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products

Stem Cells

Volumn 30, Issue 1, 2012, Pages 42-47

  Jung, Yunjoon ^a,b   Bauer, Gerhard ^b,c   Nolta, Jan A ^a,b,c  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular therapy; Clinical trials; Induced pluripotent stem cells; Mesenchymal stem cells; Regenerative medicine

Indexed keywords

CELL THERAPY AGENT; GENE THERAPY AGENT; HERMES ANTIGEN; IMMUNOSUPPRESSIVE AGENT; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2; VASCULOTROPIN;

ADIPOCYTE; AUTOIMMUNE DISEASE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLONE; CULTURE TECHNIQUE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG STERILITY; ENGRAFTMENT; EPIGENETICS; FEEDER CELL; GENE EXPRESSION; GENETIC DISORDER; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFARCTION; LUNG EMBOLISM; LYMPHATIC LEUKEMIA; MESENCHYMAL STEM CELL; MUSCLE REGENERATION; NERVE DEGENERATION; NONHUMAN; OSTEOBLAST; PARKINSON DISEASE; PATIENT SAFETY; PLURIPOTENT STEM CELL; PROTEIN MODIFICATION; REGENERATIVE MEDICINE; REVIEW; SICKLE CELL ANEMIA; SOMATIC CELL; STEM CELL EXPANSION; STEM CELL GENE THERAPY; TERATOMA; TRANSGENE; UNSPECIFIED SIDE EFFECT; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ADULT STEM CELLS; ANIMALS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MESENCHYMAL STEM CELLS; MICE; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TRANSGENES;

EID: 84855407207     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.727     Document Type: Review

References (62)

1. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010;12:87-117.
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147. (Pubitemid 28516247)
3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676. (Pubitemid 44233629)
4. Thomas ED, Ashley CA, Lochte HL, Jr. et al. Homografts of bone marrow in dogs after lethal total-body radiation. Blood 1959;14:720-736.
5. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-1826.
6. Friedenstein AJ, Chailakhyan RK, Latsinik NV et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974;17:331-340.
7. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010;16:203-209.
8. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem cell 2009;4:206-216.
9. Meyerrose T, Olson S, Pontow S et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 2010;62:1167-1174.
10. Capoccia BJ, Robson DL, Levac KD et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009;113:5340-5351.
11. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586. (Pubitemid 351626841)
12. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822. (Pubitemid 40223708)
13. Bauer G, Dao MA, Case SS et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther 2008;16:1308-1315. (Pubitemid 351866063)
14. Ripa RS, Haack-Sorensen M, Wang Y et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the stem cells in myocardial infarction (STEMMI) trial. Circulation 2007;116(11 suppl):I24-I30. (Pubitemid 47480766)
15. Joyce N, Annett G, Wirthlin L et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010;5:933-946.
16. Horwitz EM, Prockop DJ, Fitzpatrick LA et al Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313. (Pubitemid 29124367)
17. Brouard N, Chapel A, Thierry D et al. Transplantation of gene-modified human bone marrow stromal cells into mouse-human bone chimeras. J Hematother Stem Cell Res 2000;9:175-181. (Pubitemid 30305122)
18. Ding L, Lu S, Batchu R et al. Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther 1999;6:1611-1616. (Pubitemid 29465520)
19. Mosca JD, Hendricks JK, Buyaner D et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000(379 Suppl):S71-S90.
20. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-322.
21. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res 2008;314:1937-1944.
22. Wernig M, Zhao JP, Pruszak J et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105:5856-5861. (Pubitemid 351758462)
23. Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923.
24. Ebert AD, Yu J, Rose FF, Jr. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-280.
25. Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886.
26. Kambal A, Mitchell G, Cary W et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther 2011;19:584-593.
27. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317. (Pubitemid 47080336)
28. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY) 2003;302:415-419. (Pubitemid 37296260)
29. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-67.
30. Katsara O, Mahaira LG, Iliopoulou EG et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2011;20:1549-1561.
31. Hematti P. Human embryonic stem cell-derived mesenchymal progenitors: An overview. Methods Mol Biol (Clifton, NJ) 2011;690:163-174.
32. Gruenloh W, Kambal A, Sondergaard C et al. Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Tissue Eng Part A 2011;17:1517-1525.
33. Lian Q, Zhang Y, Zhang J et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010;121:1113-1123.
34. Fierro F, Kalomoiris S, Sondergaard C et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 2011 (in press).
35. Meyerrose TE, Roberts M, Ohlemiller KK et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008;26:1713-1722.
36. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006;355:1730-1735. (Pubitemid 44583964)
37. Nakagawa M, Koyanagi M, Tanabe K et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-106.
38. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCIDX1. J Clin Invest 2008;118:3132-3142.
39. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010;363:1918-1927.
40. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458.
41. Montini E, Cesana D, Schmidt M et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696. (Pubitemid 43882120)
42. Gruenloh W, Kambal A, Sondergaard C et al. Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Tissue Eng Part A 2011;17:1517-1525.
43. Gonzalez F, Boue S, Izpisua Belmonte JC. Methods for making induced pluripotent stem cells: Reprogramming a la carte. Nat Rev Genet 2011;12:231-242.
44. Zhu S, Li W, Zhou H et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010;7:651-655.
45. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471:58-62.
46. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471:68-73.
47. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7:521-531.
48. Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol 2010;28:989-990.
49. Martin MJ, Muotri A, Gage F et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11:228-232. (Pubitemid 40321360)
50. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-118.
51. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010;143:508-525.
52. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-290.
53. Cohen DE, Melton D. Turning straw into gold: Directing cell fate for regenerative medicine. Nat Rev Genet 2011;12:243-252.
54. Amariglio N, Hirshberg A, Scheithauer BW et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6:e1000029.
55. Menasche P. Cardiac cell therapy: Lessons from clinical trials. J Mol Cell Cardiol 2011;50:258-265.
56. Prasad VK, Lucas KG, Kleiner GI et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17:534-541.
57. Si YL, Zhao YL, Hao HJ et al. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev 2011;10:93-103.
58. Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 2011;22:257-262.
59. Tolar J, Le Blanc K, Keating A et al. Concise review: Hitting the right spot with mesenchymal stromal cells. Stem Cells 2010;28:1446-1555.
60. Rosova I, Dao M, Capoccia B et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173-2182.
61. Wagner J, Kean T, Young R et al. Optimizing mesenchymal stem cell-based therapeutics. Curr Opin Biotechnol 2009;20:531-536.
62. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14:181-187. (Pubitemid 351214550)